SRR1331511
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.463
- PANCREAS_BETA_CELLS+0.441
- INFLAMMATORY_RESPONSE+0.402
- COAGULATION+0.311
- IL6_JAK_STAT3_SIGNALING+0.250
- ESTROGEN_RESPONSE_LATE+0.246
- TNFA_SIGNALING_VIA_NFKB+0.245
- ALLOGRAFT_REJECTION+0.231
- KRAS_SIGNALING_UP+0.212
- COMPLEMENT+0.178
Top 10 suppressed
- DNA_REPAIR-0.535
- PROTEIN_SECRETION-0.508
- OXIDATIVE_PHOSPHORYLATION-0.504
- MYC_TARGETS_V1-0.493
- MYC_TARGETS_V2-0.485
- MITOTIC_SPINDLE-0.447
- E2F_TARGETS-0.379
- UNFOLDED_PROTEIN_RESPONSE-0.347
- G2M_CHECKPOINT-0.323
- ADIPOGENESIS-0.316
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1500617 | GTEX | — | 0.942 |
| 2 | SRR1354577 | GTEX | — | 0.938 |
| 3 | SRR1394343 | GTEX | — | 0.936 |
| 4 | SRR1476614 | GTEX | — | 0.934 |
| 5 | SRR1370473 | GTEX | — | 0.933 |
| 6 | SRR1395951 | GTEX | — | 0.933 |
| 7 | MNG907 | — | — | 0.932 |
| 8 | SRR1418604 | GTEX | — | 0.932 |
| 9 | SRR1490613 | GTEX | — | 0.929 |
| 10 | SRR1103048 | GTEX | — | 0.928 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.463 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.441 | Cobimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.402 | Idelalisib | — uncovered |
| COAGULATION | 0.311 | Binimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.250 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.246 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.245 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.231 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.212 | Inavolisib | — uncovered |
| COMPLEMENT | 0.178 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.167 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.154 | Temsirolimus | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.140 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.137 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.127 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.107 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.104 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.101 | Idelalisib | — uncovered |
| APOPTOSIS | 0.046 | Idelalisib | — uncovered |
| MYOGENESIS | 0.042 | Inavolisib | — uncovered |